影响胆囊癌的炎症指标及治疗

Inflammatory Indexes Affecting Gallbladder Carcinoma and Its Treatment

胆囊癌(GBC)是一种高度恶性的肿瘤,占胆道恶性肿瘤的80%~95%。胆囊癌在所有胆囊切除术中的发生率为0.2%~3%,在所有腹腔镜胆囊切除术中的发生率为0.09%~2%。手术切除是胆囊癌唯一的根治办法。手术应根据TNM分期决定手术切术范围,充分的术前评估对于提高根治率改善病人预后极为重要。胆囊癌的预后较差,总的5年生存率不到5%。在疾病早期,如果进行分期调整治疗,5年生存率可达75%。其发病率较低,症状不清,导致大多数患者在诊断时表现为晚期,导致其预后差。胆囊癌的全身化疗方案与胆管癌相似,包括吉西他滨和顺铂一线化疗,FOLFOX第二线化疗方案。目前正在进行的第三阶段临床试验可能会改变这种癌症的系统治疗模式。

Gallbladder carcinoma (GBC) is a highly malignant tumor, accounting for 80%~95% of biliary ma-lignancies. The incidence of gallbladder cancer is 0.2%~3% in all cholecystectomies and 0.09%~2% in all laparoscopic cholecystectomies. Surgical excision is the only cure for gallbladder cancer. The scope of surgical resection should be determined according to TNM staging. Adequate preoperative evaluation is very important to improve the radical rate and prognosis of patients. Gallbladder can-cer has a poor prognosis, with an overall 5-year survival rate of less than 5%. In the early stages of the disease, with stage-adjusted treatment, the 5-year survival rate is 75%. Its low incidence and unclear symptoms result in the late stage of diagnosis in most patients, resulting in a poor progno-sis. The systemic chemotherapy regimen for gallbladder cancer is similar to that for cholangiocar-cinoma, including first-line chemotherapy with gemcitabine and cisplatin and second-line chemo-therapy with FOLFOX. A Phase 3 clinical trial currently underway could change the systematic treatment paradigm for this cancer.